ATE547415T1 - Inhibitoren der wechselwirkung zwischen mdm2 und p53 - Google Patents
Inhibitoren der wechselwirkung zwischen mdm2 und p53Info
- Publication number
- ATE547415T1 ATE547415T1 AT08804483T AT08804483T ATE547415T1 AT E547415 T1 ATE547415 T1 AT E547415T1 AT 08804483 T AT08804483 T AT 08804483T AT 08804483 T AT08804483 T AT 08804483T AT E547415 T1 ATE547415 T1 AT E547415T1
- Authority
- AT
- Austria
- Prior art keywords
- mdm2
- interaction
- inhibitors
- compounds
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97424007P | 2007-09-21 | 2007-09-21 | |
EP07116897 | 2007-09-21 | ||
PCT/EP2008/062551 WO2009037343A1 (en) | 2007-09-21 | 2008-09-19 | Inhibitors of the interaction between mdm2 and p53 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE547415T1 true ATE547415T1 (de) | 2012-03-15 |
Family
ID=39047055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08804483T ATE547415T1 (de) | 2007-09-21 | 2008-09-19 | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
Country Status (8)
Country | Link |
---|---|
US (2) | US8288377B2 (de) |
EP (1) | EP2203447B1 (de) |
JP (1) | JP5438008B2 (de) |
AT (1) | ATE547415T1 (de) |
AU (1) | AU2008300483B2 (de) |
CA (1) | CA2699707C (de) |
ES (1) | ES2382701T3 (de) |
WO (1) | WO2009037343A1 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008210434C8 (en) | 2007-01-31 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
BRPI0809366B8 (pt) | 2007-03-28 | 2021-05-25 | Harvard College | polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica |
BRPI1008855B8 (pt) | 2009-02-04 | 2021-05-25 | Janssen Pharmaceutica Nv | derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende |
CN104876938A (zh) | 2009-11-12 | 2015-09-02 | 密歇根大学董事会 | 螺-吲哚酮mdm2拮抗剂 |
US8658170B2 (en) | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
WO2012012653A1 (en) * | 2010-07-21 | 2012-01-26 | Errico Joseph P | Combination therapy with mdm2 and efgr inhibitors |
UY33725A (es) | 2010-11-12 | 2012-06-29 | Sanofi Sa | Antagonistas de mdm2 de espiro-oxindol |
EP2707372B1 (de) | 2011-05-11 | 2016-12-21 | The Regents Of The University Of Michigan | Spiro-oxindol-mdm2-antagonisten |
CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
CA2853729A1 (en) | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
US8927500B2 (en) * | 2012-02-15 | 2015-01-06 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
JP6526563B2 (ja) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | 二置換アミノ酸ならびにその調製および使用の方法 |
WO2014085486A2 (en) | 2012-11-30 | 2014-06-05 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin d metabolites |
RU2690663C2 (ru) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Замещенные имидазопиридины в качестве ингибиторов hdm2 |
EP2999470B1 (de) * | 2013-05-22 | 2017-08-16 | Children's Hospital Medical Center | Kombinationstherapie für mds |
JP6130248B2 (ja) * | 2013-07-04 | 2017-05-17 | 公益財団法人微生物化学研究会 | 新規化合物キノフラシン類、その製造方法、及びその用途、並びに新規微生物 |
KR102092345B1 (ko) | 2013-09-30 | 2020-03-24 | 삼성전자주식회사 | 류신 지퍼 변이체 및 이의 용도 |
MX370535B (es) | 2013-11-18 | 2019-12-17 | Forma Therapeutics Inc | Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer. |
EP3071205B1 (de) | 2013-11-18 | 2020-02-05 | Forma Therapeutics, Inc. | Benzopiperazinzusammensetzungen als bet-bromdomänenhemmer |
CA2934788C (en) * | 2014-01-09 | 2021-12-07 | Orion Corporation | Bicyclic heterocyclic derivatives as bromodomain inhibitors |
WO2015107427A2 (en) * | 2014-01-17 | 2015-07-23 | Jaber Alexander | Tactical personal surveillance and monitoring system |
US10905739B2 (en) | 2014-09-24 | 2021-02-02 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
RU2743432C2 (ru) | 2016-04-06 | 2021-02-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Деструкторы белка mdm2 |
US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
US11542261B2 (en) | 2016-08-17 | 2023-01-03 | Children's Hospital Medical Center | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors |
US11254667B2 (en) | 2016-08-17 | 2022-02-22 | Children's Hospital Medical Center | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors |
US11547696B2 (en) | 2016-10-28 | 2023-01-10 | Children's Hospital Medical Center | Methods and compositions for treatment of myelodysplastic syndromes and/or acute myeloid leukemias |
ES1175583Y (es) * | 2016-10-31 | 2017-04-24 | Fermax Design & Dev S L U | Portero electronico accesible. |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
JP2000226373A (ja) * | 1998-04-08 | 2000-08-15 | Takeda Chem Ind Ltd | アミン誘導体、その製造法および剤 |
KR101331786B1 (ko) * | 2004-09-22 | 2013-11-21 | 얀센 파마슈티카 엔.브이. | Mdm2 및 p53간의 상호작용 저해제 |
EP2001868B1 (de) * | 2006-03-22 | 2013-07-17 | Janssen Pharmaceutica N.V. | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
US8088795B2 (en) | 2006-03-22 | 2012-01-03 | Janssen Pharmaceutica N.V. | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53 |
-
2008
- 2008-09-19 WO PCT/EP2008/062551 patent/WO2009037343A1/en active Application Filing
- 2008-09-19 AT AT08804483T patent/ATE547415T1/de active
- 2008-09-19 JP JP2010525363A patent/JP5438008B2/ja active Active
- 2008-09-19 EP EP08804483A patent/EP2203447B1/de active Active
- 2008-09-19 AU AU2008300483A patent/AU2008300483B2/en not_active Ceased
- 2008-09-19 ES ES08804483T patent/ES2382701T3/es active Active
- 2008-09-19 US US12/678,680 patent/US8288377B2/en active Active
- 2008-09-19 CA CA2699707A patent/CA2699707C/en active Active
-
2012
- 2012-09-07 US US13/606,468 patent/US20130005769A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100216770A1 (en) | 2010-08-26 |
US8288377B2 (en) | 2012-10-16 |
CA2699707C (en) | 2016-05-17 |
ES2382701T3 (es) | 2012-06-12 |
EP2203447A1 (de) | 2010-07-07 |
CA2699707A1 (en) | 2009-03-26 |
WO2009037343A1 (en) | 2009-03-26 |
AU2008300483A1 (en) | 2009-03-26 |
AU2008300483B2 (en) | 2013-01-10 |
JP5438008B2 (ja) | 2014-03-12 |
EP2203447B1 (de) | 2012-02-29 |
US20130005769A1 (en) | 2013-01-03 |
JP2010539223A (ja) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE547415T1 (de) | Inhibitoren der wechselwirkung zwischen mdm2 und p53 | |
ATE470665T1 (de) | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 | |
TW200626579A (en) | Inhibitors of the interaction between MDM2 and p53 | |
DK2134691T3 (da) | Quinolinonderivativer som parp- og tank-inhibitorer | |
TW200610531A (en) | Phthalazine derivatives as PARP inhibitors | |
JO2704B1 (en) | Interference inhibition factors between MD2 and B53 | |
IL185275A0 (en) | N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same | |
EA200970156A1 (ru) | Пиридизиноновые производные | |
EA200500203A1 (ru) | Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат | |
SG154434A1 (en) | Quinazolinone derivatives as parp inhibitors | |
EA201070278A1 (ru) | Ингибиторы гамма-секретазы | |
EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
EA200700185A1 (ru) | Производные хиназолиндиона в качестве ингибиторов parp | |
MX2010010406A (es) | Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina. | |
CY1110010T1 (el) | Πυριδιναμινοσουλφονυλ υποκατεστημενα βενζαμιδια ως αναστολεις κυτοχρωματος ρ450 3α4 (cyp3a4) | |
CY1109331T1 (el) | Παραγωγα αμινοφαινυλιου ως νεοι αναστολεις της αποακετυλασης ιστονης | |
EA201270590A1 (ru) | Ингибиторы акт | |
DK1899325T3 (da) | Imidazolinon- og hydantoinderivater som hidtil ukendte hæmmere af histondeacetylase | |
EA200801145A1 (ru) | Спироциклические производные хиназолина в качестве ингибиторов pde7 | |
CY1113409T1 (el) | Αναστολεις ακτ και ρ70 s6 κινασης | |
EA201101334A1 (ru) | Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их | |
RS51661B (en) | NEW DIOSMETHINE DERIVATIVES, THE PROCEDURE FOR THEIR MAKING AND THE PHARMACEUTICAL MIXTURES CONTAINING THEM | |
EA201200891A1 (ru) | Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина | |
GEP20135959B (en) | Aryl piperazine and their usage as alpha2c antagonists | |
SE0303541D0 (sv) | New compounds |